Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

The Jekyll and Hyde of Extracellular Vesicles: Dual Roles as Disease Drivers and Therapeutic Saviors in Diabetic Brain.

Li H., He R., Luo T., Ou C., Hu Y.

Narrative Review on Neuroinflammation, published in Mol Neurobiol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Mol Neurobiol (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41721937
DOI
10.1007/s12035-026-05725-y

Abstract (original English)

Diabetes-associated cognitive impairment (DACI) represents a debilitating complication lacking effective therapeutics. Extracellular vesicles (EVs) demonstrate a paradoxical dual role in DACI pathophysiology. Under diabetic conditions, EVs secreted by metabolically dysregulated adipose tissue and activated circulating inflammatory cells deliver neurotoxic cargo (miR-9-3p, miR-125a-5p) inducing neuronal ferroptosis, synaptic loss, and blood-brain barrier disruption via MEK/ROCK signaling. Brain-derived EVs enriched in complement proteins and mitochondrial markers serve as minimally invasive diagnostic biomarkers validated in multicenter cohorts. Conversely, mesenchymal stem cell-derived and brain endothelial cell-derived EVs exhibit substantial therapeutic potential, attenuating neuroinflammation, promoting neurogenesis, and restoring cognitive function across preclinical models. Clinical translation confronts challenges in GMP-compliant manufacturing, regulatory harmonization, and standardized potency assays. Engineering strategies encompassing cargo optimization and surface modification for brain targeting offer transformative solutions. This review establishes an integrated framework for developing EV-based diagnostics and therapeutics to address this prevalent complication.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Extracellular VesiclesHumansAnimalsBrainDiabetes MellitusDiabetes ComplicationsBiomarkers

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research